Patient-derived organoids (PDOs) have recently emerged as robust preclinical models;
however, their potential to predict clinical outcomes in patients has remained unclear. We …

Clear cell renal cell carcinoma (ccRCC) is characterized by near-universal loss of the short
arm of chromosome 3, deleting several tumor suppressor genes. We analyzed whole …

The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been
systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients …

With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we
demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab …

CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a
target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited …

ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …

Opinion statement The treatment of advanced GIST is rapidly evolving with the development
of novel molecular compounds such as avapritinib and ripretinib, but also promising results …

Hemophilic arthropathy (HA) contributes the greatest morbidity and cost in the hemophilic
population. Imaging plays a crucial role in accurately monitoring the disease process in all …

Background & Aims Cholangiocarcinomas (CCA) are resistant to chemotherapy, so new
therapeutic agents are needed. We performed a screen to identify small-molecule …

Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic
Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell …